An early increase in eosinophil count during the treatment with ipilimumab was associated with an improved clinical response. In addition, the content of eotaxin-1 in serum from nonresponding melanoma patients was significantly lower than before the therapy. This chemokine is considered to play a critical role in the eosinophil recruitment. This evidence concerns the gene CCL11 and melanoma.